A shorter treatment for rifampicin-resistant TB
Part of Infections clinical trials.
This trial tests a 6-month treatment for people with rifampicin-resistant tuberculosis (TB). It aims to see if a shorter, simpler regimen works as well as longer treatments. You may qualify if you have this type of TB and meet a few health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years or older.
- You have rifampicin-resistant TB in your lungs, confirmed by a test within the last 8 weeks.
- You weigh at least 30 kg (about 66 pounds).
- You have not started TB treatment yet, or started it within the last 10 days.
- You agree to HIV testing (if not already done) and, if HIV-positive, are on or willing to start antiretroviral therapy.
- You do not have severe liver, kidney, or heart problems, and you can take the study drugs safely.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a shorter, all-oral treatment for people with Rifampicin-resistant TB. It aims to see if a new combination of drugs works well and safely over a shorter time.
This Phase 3 trial tests a shorter, all-pill (oral) treatment plan for people with rifampicin-resistant pulmonary tuberculosis. It aims to improve treatment while reducing the burden of therapy, using a plan tailored to the individual.
This trial tests a shorter treatment for TB that is resistant to the drug rifampicin but still sensitive to isoniazid. It may help people finish treatment sooner and with fewer side effects.
This trial tests whether a shorter, rifampicin-based treatment works well for people with less severe TB in the lungs. If you have limited TB that is sensitive to rifampicin, you might be able to take medicine for a shorter time than usual.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This trial tests a shorter treatment regimen for people with tuberculosis (TB) who don't have symptoms. If you have TB bacteria in your lungs but no cough, fever, night sweats, or weight loss, this study may offer a more convenient treatment option.
Hear when a new Rifampicin-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.